Biocon Ltd (BIOCON)
₹433.65
Mkt cap
₹70,672 Cr
P/E ratio
182.00
P/B
2.07
Div yield
0.12%
ROE
1.40%
ROCE
3.61%
EPS (TTM)
₹2.38
Book value
₹210
52W range
339–441
Sector
Healthcare
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)
Health check
Mixed
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsBullish
52-week range
−1.60% from high₹434
₹339+27.96% from low₹441
Current
₹433.65
Prev close
₹434.20
Day
−0.13%
Price performance
1D
−0.13%
1W
−0.65%
1M
+4.21%
3M
+23.95%
6M
+18.21%
1Y
+9.23%
YTD
+10.36%
Financials
FRevenue, profit & margin
P/E ratio
182.0×
BIOCON is 435% above the sector median of 34.0×
BIOCON182.0×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | |
| Expenses | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,193 | 3,460 | 3,340 | 3,496 | |
| Operating Profit | 957 | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 749 | 835 | 834 | 1,020 | |
| OPM % | 25% | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% | 19% | 20% | 23% | |
| Other Income | 152 | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 80 | 81 | -176 | -28 | |
| Interest | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 | 232 | |
| Depreciation | 364 | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 | 513 | |
| Profit before tax | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 | 248 | |
| Tax % | 17% | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% | 22% | -24% | 20% | |
| Net Profit | 414 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 | 199 | |
| EPS in Rs | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 | 0.63 | 1.08 | 0.78 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.85% · closed higher next day 18 of last 58
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 11 Aug '23◦ | 11 Nov '23◦ | 9 Feb '24◦ | 16 May '24◦ | 9 Aug '24 | 30 Oct '24◦ | 31 Jan '25 | 8 May '25◦ | 7 Aug '25◦ | 11 Nov '25◦ | 12 Feb '26◦ | 8 May '26 |
| Earnings day | −0.62% | −0.02% | −2.45% | +0.03% | −0.65% | −1.43% | +1.55% | −1.40% | −5.72% | +5.40% | +0.77% | −0.48% |
| +1 day | +0.37% | +0.75% | −2.27% | −0.39% | −0.38% | −3.06% | +3.77% | −1.93% | −6.07% | +8.28% | +1.41% | +2.15% |
| +5 days | +1.48% | +2.77% | +6.46% | +4.48% | +1.67% | +0.19% | +11.19% | +1.43% | +0.03% | +6.49% | +2.37% | +12.52% |
| +15 days | +4.25% | +5.72% | +2.01% | +9.89% | +7.15% | +9.96% | −5.88% | +0.37% | −2.22% | +6.47% | +3.91% | +11.35% |
| +30 days | +3.30% | +8.77% | −6.14% | +16.97% | +9.20% | +9.43% | −6.65% | +5.01% | −1.29% | +3.44% | −2.63% | +10.16% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Re 0.50 Per Share | — | 3 Jul '26 | 3 Jul '26 |
Shareholding
Sas of Jun 202644.68%Promoter
Promoters44.68%0.23
FIIs8.14%0.62
DIIs23.33%0.68
Public23.75%0.35
Government0.05%
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Biocon | ₹433.65 | 181.76 | 70,672 | 0.12% | 199 | −62.05% | 4,517 | +2.25% | 3.61% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts110
TranscriptJun 2026PPTJun 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026PPTDec 2025PPTDec 2025TranscriptDec 2025PPTDec 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024PPTJun 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Change in Directorate 1d - Biocon’s Independent Director Bobby Kanubhai Parikh ceased July 22, 2026 after completing second term.Announcement under Regulation 30 (LODR)-Newspaper Publication 16 JulCompany Statement 16 Jul - Biocon Malaysia gets EMA approval for Semglee fill-finish line; Europe supplies expectedQ2FY27.Business Responsibility and Sustainability Reporting (BRSR) 15 Jul - Biocon issued FY26 annual report and AGM notice; AGM on August 6, 2026, dividend payment by August 20.Reg. 34 (1) Annual Report. 15 Jul - Biocon to hold 48th AGM on August 6, 2026; annual report released; final dividend payable by August 20.